Peritoneal metastasiertes Ovarialkarzinom

Aletti GD, Dowdy SC, Gostout BS et al. (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107: 77–85 Armstrong DK, Bundy B, Wenzel L et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43 Bristow RE, Tomacruz RS, Armstrong DK et al. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20: 1248–1259 Cliby W, Dowdy S, Feitoza SS et al. (2004) Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol 94: 655–660 du Bois A, Rochon J, Lamparter C, Pfisterer J (2005) Ovarialkarzinom – Versorgungsstruktur und -qualität in Deutschland 2001–2004. Frauenarzt 46: 560–567 Eisenhauer EL, Abu-Rustum NR, Sonoda Y et al. (2006) The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103: 1083–1090 Eisenkop SM, Spirtos NM (2001) What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 82: 489–497 Elit L, Chartier C, Oza A et al. (2006) Outcomes for systemic therapy in women with ovarian cancer. Gynecol Oncol 103: 554–558 Estes JM, Leath CA 3rd, Straughn JM Jr et al. (2006) Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg 203: 527–532 Fanning J, Hilgers RD (1995) Loop electrosurgical excision procedure for intensified cytoreduction of ovarian cancer. Gynecol Oncol 57: 188–190 Hoffman MS, Griffin D, Tebes S et al. (2005) Sites of bowel resected to achieve optimal ovarian cancer cytoreduction: implications regarding surgical management. Am J Obstet Gynecol 193: 582–586 Kommission Ovar der AGO (2007) Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren. Zuckschwerdt, Germering Piso P, Dahlke MH, Loss M, Schlitt HJ (2004) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2: 21 Rose PG (1992) The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol 166: 843–846 Rose PG, Nerenstone S, Brady MF et al. Gynecologic Oncology Group (2004) Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351: 2489–2497 Tebes SJ, Cardosi R, Hoffman MS (2006) Colorectal resection in patients with ovarian and primary peritoneal carcinoma. Am J Obstet Gynecol 195: 585–589 Burg ME van der, Lent M van, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332: 629–634 Walker JL, Armstrong DK, Huang HQ et al. (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100: 27–32 Wenzel LB, Huang HQ, Armstrong DK et al. (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 437–443